Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer

Predictive utility of tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy (NAC) with concurrent trastuzumab remains unclear. We examined TILs grades of pretreatment cancer tissue specimens and residual tumors after NAC with trastuzumab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367461/
https://www.ncbi.nlm.nih.gov/pubmed/30733496
http://dx.doi.org/10.1038/s41598-018-38272-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367461/
https://www.ncbi.nlm.nih.gov/pubmed/30733496
http://dx.doi.org/10.1038/s41598-018-38272-1

Ejemplares similares